Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Melanoma 2Vasculitis 1Unspecified Adult Solid Tumor, Protocol Specific 1Stomach Neoplasms 1Osteomyelitis 1Neoplasms 1Lymphoma 1Lung Neoplasms 1Heart Diseases 1Head and Neck Neoplasms 1Fever of Unknown Origin 1Dementia 1Colonic Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Cyclophosphamide 22Trastuzumab 16Paclitaxel 15Radiotherapy 13Docetaxel 13Capecitabine 11Doxorubicin 10Taxes 9Lapatinib 9Carboplatin 8Tamoxifen 7Immunohistochemistry 7Biopsy 7Albumin-Bound Paclitaxel 7Magnetic Resonance Spectroscopy 6Fluorodeoxyglucose F18 6Chemotherapy, Adjuvant 6Immunoenzyme Techniques 5Gemcitabine 5Flow Cytometry 5Bevacizumab 5sargramostim 4Vinorelbine 4Letrozole 4Irinotecan 4Granulocyte-Macrophage Colony-Stimulating Factor 4Filgrastim 4Everolimus 4Erlotinib Hydrochloride 4Cisplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Breast Neoplasms, Male × Tomography, Emission-Computed × Clear all
NCT01931709 2023-11-18

FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer

University of Washington

Phase NA Terminated
35 enrolled 11 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡